Tepmetko (tepotinib) / EMD Serono - LARVOL DELTA

IFCT-2404 COMET: a phase III trial of tepotinib versus investigator's choice in patients with pre-treated MET exon 14-mutated NSCLC (ESMO 2026) - No abstract available

Clinical • P3 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • MET

Pulse dexamethasone for Tepotinib associated oedema management in MET exon 14 skipping mutation Lung Adenocarcinoma (LAC) patients: Single Centre experience from United Kingdom (ESMO 2026) - No abstract available

Clinical • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • MET

Health-related quality of life (HRQoL) with tepotinib in patients with MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC) with brain, liver, adrenal, or bone metastases in the phase II VISION trial. (ASCO 2024) - P2 | "In the VISION trial in METex14 skipping NSCLC, patients with brain, liver, adrenal or bone metastases maintained overall HRQoL during tepotinib treatment, with trends for improvement in cough, consistent with results for the overall population. 1. Mazieres et al."

Clinical • HEOR • P2 data • Cough • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pain • Pulmonary Disease • Respiratory Diseases • Solid Tumor • MET

Alteration-Matched Therapy in Advanced Lung Cancer: Results From the IMPRESS-Norway Study (IASLC-WCLC 2026) - P2 | "Among 27 evaluable patients, the DCR at week 16 was 29.6%, including 3 partial responses and 5 cases of stable disease observed with pertuzumab plus trastuzumab, tepotinib and olaparib. The DCR of nearly 30% with partial responses in selected cohorts suggests clinical benefit in a population with limited treatment options. Grade ≥3 TRAEs occured in 28% of patients with no grade 5 toxicity, indicating a manageable safety profile."

Metastases • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • HER-2 • MET

Long-term outcomes of tepotinib in patients with MET exon 14 skipping NSCLC from the VISION study. (ASCO 2023) - P2 | "The long-term outcomes of VISION demonstrate the robust and durable clinical activity of tepotinib, particularly in 1L T+ pts, and manageable safety profile, further defining its use in clinical practice. Clinical trial information: NCT02864992. >"

Clinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • MET

Liquid and tissue biopsies for identifying MET exon 14 skipping NSCLC: Analyses from the Phase II VISION study of tepotinib. (PubMed, Clin Cancer Res) - "Tepotinib had robust, durable activity in TBx-positive/LBx-negative and TBx-positive/LBx-positive patients. While LBx is a complementary method to TBx for detecting METex14, it may preferentially select patients with higher tumor burden and poorer prognosis. Undetectable METex14 in baseline ctDNA (due to low ctDNA shedding) may define more favorable treatment outcomes."

Journal • P2 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • MET

Amivantamab in patients with NSCLC with MET exon 14 skipping mutation: Updated results from the CHRYSALIS study. (ASCO 2022) - P1 | "Median age was 70 y (range, 43-88), 58% were women, median prior lines of therapy was 2 (range, 0-10) [eg, crizotinib (n=13), capmatinib (n=11), tepotinib (n=5), anti-MET antibody (n=1)], and 23% had history of brain metastases at baseline. Amivantamab demonstrates anti-tumor activity in primary METex14 NSCLC including after prior MET inhibitor treatment. Enrollment is ongoing and updated data will be shown."

Clinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR • MET

Tepotinib + osimertinib for EGFR mutant (EGFRm) NSCLC with MET amplification (METamp) after first-line (1L) osimertinib. (ASCO 2023) - P2 | "In this interim analysis of INSIGHT 2, tepotinib + osimertinib was highly active with durable responses, and was well tolerated in pts with EGFRm NSCLC with METamp after progression on 1L osimertinib. Tepotinib + osimertinib provides a potential chemotherapy-sparing oral targeted therapy option in this population with a high unmet need. Clinical trial information: NCT03940703."

Clinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR • MET

Understanding tumor adaptations and resistance to MET inhibitors in MET-altered non-small cell lung cancer. (PubMed, Neoplasia) - "MET inhibitor resistance in this cohort involved overlapping, context-dependent genomic, phenotypic, and signaling adaptations, supporting combination strategies for MET-altered lung cancer."

Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR • FN1

Tepotinib in patients with non-small cell lung cancer with high-level MET amplification detected by liquid biopsy: VISION Cohort B. (PubMed, Cell Rep Med) - P2 | "Adverse events include edema (composite term; any grade: 58.3%; grade 3: 12.5%) and constipation (any grade: 41.7%; grade 3: 4.2%). Tepotinib provides antitumor activity in high-level METamp NSCLC (ClinicalTrials.gov: NCT02864992)."

Biopsy • Journal • Liquid biopsy • Constipation • Gastroenterology • Gastrointestinal Disorder • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • MET • RB1

Tepotinib + Osimertinib in EGFR-mutant NSCLC with MET Amplification Following 1L Osimertinib: INSIGHT 2 Primary Analysis (IASLC-WCLC 2023) - P2 | "Tepotinib + osimertinib demonstrated durable responses and a manageable safety profile in patients with EGFRm METamp NSCLC following 1L osimertinib, especially in Asian patients. Tepotinib + osimertinib provides a potential chemotherapy-sparing oral targeted therapy option in this population with a high unmet need."

Inflammation • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pneumonia • Solid Tumor • EGFR • MET

Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial. (PubMed, Lancet Oncol) - P2 | "Tepotinib plus osimertinib showed promising activity and acceptable safety in patients with EGFR-mutated NSCLC and MET amplification as a mechanism of resistance to first-line osimertinib, suggesting a potential chemotherapy-sparing oral targeted therapy option that should be further investigated."

Journal • P2 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pneumonia • Pulmonary Disease • Respiratory Diseases • Solid Tumor • EGFR • MET

A phase II study of tepotinib in patients with advanced solid cancers harboring MET exon 14 skipping mutations or amplification (KCSG AL19-17). (PubMed, ESMO Open) - "Tepotinib demonstrated consistent antitumor activity in patients with METex14, and promising antitumor activity in various cancers with MET amplification. Detection of MET dysregulation by plasma NGS may predict the response to tepotinib."

Clinical • Journal • Metastases • P2 data • Anorexia • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • MET

Real-world safety assessment of MET-targeted therapies: a pharmacovigilance analysis using the FAERS database. (PubMed, Drugs Context) - "In cluster analysis, key adverse drug reactions (e.g. infusion-related reactions for amivantamab, hepatotoxicity for savolitinib, peripheral swelling for capmatinib and peripheral oedema for tepotinib) primarily occur as isolated events with limited co-occurrence of multiple toxicities. These findings support individualized monitoring and evidence-based treatment selection for older patients, those with comorbidities or patients at high risk with MET-altered NSCLC."

Adverse events • Journal • Real-world evidence • Hematological Disorders • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pulmonary Disease • Solid Tumor • HGF

Management of Adverse Events Associated with MET TKIs in Patients with Advanced NSCLC: A Podcast Discussion. (PubMed, Target Oncol) - "Among these MET TKIs, tepotinib and capmatinib are globally approved and have demonstrated robust and durable efficacy in patients with METex14 skipping NSCLC in the VISION and GEOMETRY mono-1 trials. They will also share their perspectives on the current landscape of MET TKIs in METex14 skipping NSCLC, commonly reported TRAEs in clinical practice, management strategies for these TRAEs, and safety considerations when switching one MET TKI to another. In addition, authors will discuss two patient cases to illustrate effective management of TRAEs associated with MET TKIs in patients with METex14 skipping NSCLC."

Adverse events • Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • MET

Randomized Trial of Tepotinib Plus Gefitinib Versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis. (PubMed, Clin Cancer Res) - "Final analysis of INSIGHT suggests improved PFS and OS with tepotinib plus gefitinib versus chemotherapy in a subgroup of patients with MET-amplified EGFR-mutant NSCLC, after progression on EGFR inhibitors."

Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • MET

Improving public cancer care by implementing precision medicine in Norway (clinicaltrialsregister.eu) - P1/2 | N=1000 | Recruiting | Sponsor: Oslo University Hospital HF | N=6000 ➔ 1000

Enrollment change • Oncology

Pan-RAS(on) Inhibitors RMC-6236 and GFH276 With Omeprazole or Ensartinib in KRAS-mutant Lung Cancer Cells (IASLC-WCLC 2026) - "Our previous work showed that the combination of omeprazole plus tepotinib is active in KRAS-mutant G12C and non-G12C cell lines ( Rosell et al...The H23 and A549 (sotorasib-resistant) cells were sensitive to both Pan-RAS(ON) inhibitors with higher IC 50s...Finally, pretreatment with omeprazole plus Pan-RAS inhibitors suggests a potential to delay resistance. Like crizotinib, ensartinib has activity against ALK, ROS1, and MET, and additionally targets AXL; therefore, ensartinib warrants further investigation."

Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • AXL • CTNNB1 • KRAS • ROS1 • SQSTM1 • STAT3

Influence of Major Histocompatibility Complex (MHC) Diversity on Immune Modulation, Pathogenesis, and Control of Lumpy Skin Disease Virus. (PubMed, Recent Adv Antiinfect Drug Discov) - "Lumpy Skin Disease continues to pose a major threat to global cattle health and livestock economies. Advances in molecular diagnostics, genomic surveillance, antiviral drug discovery, and BoLA-guided vaccine design provide promising opportunities for improved disease control. Understanding the interaction between LSDV and the bovine MHC system is essential for developing next-generation vaccines, immunotherapeutics, and precision disease-management strategies. Future research should prioritise experimental validation of predicted epitopes, large-scale vaccine trials, and mechanistic studies on host-virus immune interactions to establish effective and sustainable global control programs for LSDV."

IO biomarker • Journal • Dermatology • Dermatopathology • Immune Modulation • Immunology • Infertility • Sexual Disorders

Tepotinib + osimertinib for EGFRm NSCLC with MET amplification (METamp) after progression on first-line (1L) osimertinib: Initial results from the INSIGHT 2 study (ESMO 2022) - P2 | "† Incomplete post-baseline assessments (n=2), SD <12 weeks (n=3), COVID-19-related early discontinuation (n=1), and PD/AE-related-early discontinuations (n=5). Conclusions In this initial analysis of INSIGHT 2, TEP+OSI was highly active and well tolerated in pts with EGFRm NSCLC with METamp after progression on 1L osimertinib and enables continuation of oral-only chemo-sparing therapy in this population with a high unmet need."

Clinical • Late-breaking abstract • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • MET

Persistence and adherence to tepotinib in patients with metastatic non-small cell lung cancer: a real-world evidence study including dose reductions. (PubMed, Future Oncol) - "Tepotinib therapy showed consistent real-world persistence and adherence among patients with metastatic NSCLC. Dose reductions supported continuity of tepotinib therapy."

HEOR • Journal • Real-world evidence • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial. (PubMed, JAMA Oncol) - P2 | "The findings from cohort C in this nonrandomized clinical trial supported the results from original cohort A. Overall, the long-term outcomes of VISION demonstrated robust and durable clinical activity following treatment with tepotinib, particularly in the treatment-naive setting, in the largest known clinical trial of patients with METex14-skipping NSCLC, supporting the global approvals of tepotinib and enabling clinicians to implement this therapeutic approach for such patients. ClinicalTrials.gov Identifier: NCT02864992"https://clinicaltrials.gov/ct2/show/NCT02864992"."

Clinical • Journal • P2 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • MET

Tepotinib in Patients with MET Exon 14 (METex14) Skipping NSCLC: Primary Analysis of the Confirmatory VISION Cohort C (IASLC-WCLC 2022) - "In VISION - the largest clinical trial of a MET inhibitor in METex14 skipping NSCLC - Cohort C primary analysis provided independent confirmation for robust and durable efficacy of tepotinib, with comparable or improved outcomes across endpoints compared to Cohort A. Efficacy was particularly durable in 1L T+ patients and promising intracranial activity was observed."

Clinical • Immunology • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • MET

Tepotinib outcomes according to prior therapies in patients with MET exon 14 (METex14) skipping NSCLC (ESMO 2022) - P2 | "Treatment-related adverse events (TRAEs) occurred in 91.7% of pts (1L: 94.5%, ≥2L: 88.6%, prior IO: 90.1%); 34.2% had Grade ≥3 TRAEs (1L: 40.9%, ≥2L: 26.8%, prior IO: 27.2%) and 14.7% discontinued due to TRAEs (1L: 15.2%, ≥2L: 14.1%, prior IO: 17.3%). Table: 985P Conclusions In VISION – the largest study of a MET inhibitor in pts with METex14 skipping NSCLC – tepotinib demonstrated robust and durable efficacy irrespective of prior therapies and had a tolerable safety profile."

Clinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • MET

Phlegmasia Cerulea Dolens and Pulmonary Embolism in a Patient With NSCLC Receiving Dual EGFR/MET Targeted Therapy: A Case Report. (PubMed, JTO Clin Res Rep) - "We describe a 43-year-old man with metastatic EGFR-mutated NSCLC who developed extensive phlegmasia cerulea dolens and pulmonary embolism while receiving dual targeted therapy with osimertinib and tepotinib for acquired MET amplification. Early recognition of atypical limb swelling and prompt vascular assessment are essential to distinguish drug-related edema from evolving thrombosis. Further pharmacovigilance and clinical studies are needed to clarify the thrombotic safety of dual targeted therapy in NSCLC."

Journal • Cardiovascular • Hematological Disorders • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pain • Pulmonary Embolism • Respiratory Diseases • Solid Tumor • Venous Thromboembolism • EGFR